



Dear Colleagues,

As you know, SECURE-IBD has been an amazing resource for the IBD community over the last two years. It's incredible to think how far we have come and how much we have learned together. Thank you for your interest in and contributions to SECURE-IBD. This initiative would not have been possible without your support.

Through SECURE-IBD, we have learned that age and increased number of comorbidities are associated with adverse COVID-19 outcomes among patients with IBD, and that Hispanic and Black individuals with IBD tend to have worse COVID-19 outcomes than white individuals. We found that corticosteroids are associated with more severe COVID-19 outcomes, while biologic medications are not. Overall, our data have reassured the international IBD community that patients with IBD can continue their medications during the pandemic, with the caveat of weaning steroids when possible. A complete bibliography of published manuscripts is included below.

We have also learned many valuable lessons that can be applied to future projects requiring rapid data collection during a crisis. Engaging the IBD community early in the process and working with international organizations/sponsors led to a level of participation that we never dreamed possible. We remain astounded at the unwavering commitment of our community to come together to answer critically important questions for patients with IBD. Adaptability played another key role in our success; Adding new questions to our case report forms in response to emerging clinical needs and re-evaluating initial conclusions based on new data enabled us to keep pace during a rapidly changing situation.

As we move into a new phase of the pandemic with different variants, evolving vaccines and vaccination strategies, re-infections, and COVID-specific treatments, the most pressing questions have shifted away from "What are the medication and other risk factors for developing a more severe course of COVID-19 in patients with IBD?" to new questions about vaccines, immunity, testing, and treatments. As SECURE-IBD was designed to address the initial question rather than these current questions, we believe that new studies are needed and that continued reporting to SECURE-IBD will not be as valuable as earlier in the pandemic. Additionally, providers (including us) have grown tired of reporting, and the reports we continue receive are becoming less generalizable with time.

At this juncture, we believe it is time to close-down reporting to the SECURE-IBD database. SECURE-IBD served a valuable purpose at a time when our IBD community needed fast answers to pressing questions. We are proud of SECURE-IBD's contributions and incredibly grateful for your help. We look forward to future opportunities for collaboration.

With gratitude,

Erica J. Brenner, MD, MSCR (Pediatric Gastroenterologist, University of North Carolina at Chapel Hill)
Manasi Agrawal, MD, MS (Gastroenterologist, Icahn School of Medicine at Mount Sinai, New York)
Ryan Ungaro, MD, MS (Gastroenterologist, Icahn School of Medicine at Mount Sinai, New York)
Michael D. Kappelman, MD, MPH (Pediatric Gastroenterologist, University of North Carolina at Chapel Hill)
Jean-Frederic Colombel, MD (Gastroenterologist, Icahn School of Medicine at Mount Sinai, New York)

SECURE-IBD Publications

1. Kaplan GG, Underwood FE, Coward S, Agrawal M, Ungaro RC, Brenner EJ, Geary RB, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Steinwurz F, Zhang X, Kappelman MD, Colombel JF. The Multiple Waves of COVID-19 in Patients With Inflammatory Bowel Disease: A Temporal Trend Analysis. *Inflamm Bowel Dis*. 2022 Jan 15:izab339. Epub ahead of print. PMID: 35032167.
2. Sperger J, Shah KS, Lu M, Zhang X, Ungaro RC, Brenner EJ, Agrawal M, Colombel JF, Kappelman MD, Kosorok MR. Development and validation of multivariable prediction models for adverse COVID-19 outcomes in patients with IBD. *BMJ Open*. 2021 Nov 12;11(11):e049740. PMID: 34772750.
3. Izadi Z*, Brenner EJ*, Mahil SK, Dand N, Yiu ZZN, Yates M, Ungaro RC, Zhang X, Agrawal M, Colombel JF, Gianfrancesco MA, Hyrich KL, Strangfeld A, Carmona L, Mateus EF, Lawson-Tovey S, Klingberg E, Cuomo G, Caprioli M, Cruz-Machado AR, Mazedo Pereira AC, Hasseli R, Pfeil A, Lorenz HM, Hoyer BF, Trupin L, Rush S, Katz P, Schmajuk G, Jacobsohn L, Seet AM, Al Emadi S, Wise L, Gilbert EL, Duarte-García A, Valenzuela-Almada MO, Isnardi CA, Quintana R, Soriano ER, Hsu TY, D'Silva KM, Sparks JA, Patel NJ, Xavier RM, Marques CDL, Kakehasi AM, Flipo RM, Claudepierre P, Cantagrel A, Goupille P, Wallace ZS, Bhana S, Costello W, Grainger R, Hausmann JS, Liew JW, Sirotych E, Sufka P, Robinson PC, Machado PM, Griffiths CEM, Barker JN, Smith CH, Yazdany J, Kappelman MD; Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD); and the COVID-19 Global Rheumatology Alliance; Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD); and the COVID-19 Global Rheumatology Alliance (GRA). Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. *JAMA Netw Open*. 2021 Oct 1;4(10):e2129639. PMID: 34661663.
4. Ricciuto A, Lamb CA, Benchimol EI, Walker GJ, Kennedy NA, Kuenzig ME, Kaplan GG, Kappelman MD, Ungaro RC, Colombel JF, Brenner EJ, Agrawal M, Reinisch W, Griffiths AM, Sebastian S. Inflammatory Bowel Disease Clinical Activity Is Associated with COVID-19 Severity Especially in Younger Patients. *J Crohns Colitis*. 2021 Sep 27;jjab172. PMID: 34570886.
5. Ungaro RC*, Brenner EJ*, Agrawal M, Zhang X, Kappelman MD, Colombel JF; Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) Research Group. Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of Over 6,000 Patients from an International Registry. *Gastroenterology*. 2021 Sep 13. Epub ahead of print. PMID: 34529987.
6. Ungaro RC, Agrawal M, Brenner EJ, Zhang X, Colombel JF, Kappelman MD, Reinisch W. New Gastrointestinal Symptoms Are Common in Inflammatory Bowel Disease Patients With COVID-19: Data From an International Registry. *Inflamm Bowel Dis*. 2021 Jul 28:izab184. Epub ahead of print. PMID: 34320194.
7. Parekh R, Zhang X, Ungaro RC, Brenner EJ, Agrawal M, Colombel JF, Kappelman MD. Presence of Comorbidities Associated with Severe Coronavirus Infection in Patients with Inflammatory Bowel Disease. *Dig Dis Sci*. 2021 Jun 28:1–7. Epub ahead of print. PMID: 34181165.
8. Agrawal M*, Brenner EJ*, Yan Mak JW, Zhang X, Kaplan GG, Ng SC, Reinisch W, Steinwurz F, Lewis JD, Kissous-Hunt M, Modesto I, Ungaro RC, Colombel JF, Kappelman MD. COVID-19 Outcomes Among Racial and Ethnic Minority Individuals With Inflammatory Bowel Disease in the United States. *Clin Gastroenterol Hepatol*. 2021 Jun 2. Epub ahead of print. PMID: 34089848.
9. Agrawal M, Zhang X, Brenner EJ, Ungaro RC, Kappelman MD, Colombel JF. The impact of vedolizumab on COVID-19 outcomes among adult IBD patients in the SECURE-IBD registry. *J Crohns Colitis*. 2021 Apr 22. Epub ahead of print. PMID: 33884425.
10. Brenner EJ*, Ungaro RC*, Colombel JF, Kappelman MD. Reply to: Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients with Inflammatory Bowel Diseases: Results from an International Registry. *Gastroenterology*. 2021 Apr;160(5):1886-1887. Epub 2021 Jan 13. PMID: 33453233.
11. Agrawal M, Brenner EJ, Zhang X, Modesto I, Woolcott J, Ungaro RC, Colombel JF, Kappelman MD. Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry. *Inflamm Bowel Dis*. 2021 Mar 15;27(4):585-589. PMID: 33325523

12. Agrawal M, Brenner EJ, Zhang X, Colombel JF, Kappelman MD, Ungaro RC; SECURE-IBD Advisory Committee including, Geary RB, Kalpan GG, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Ruemmele FM, Steinwurz F, Underwood FE. Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry. *J Crohns Colitis*. 2021 May 4;15(5):860-863. PMID: 33232456.
13. Ungaro RC, Brenner EJ, Geary RB, Kaplan GG, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Steinwurz F, Underwood FE, Zhang X, Colombel JF**, Kappelman MD**. Effect of IBD medications on COVID-19 outcomes: results from an international registry. *Gut*. 2021 Apr;70(4):725-732. PMID: 33082265.
14. Brenner EJ*, Pigneur B*, Focht G, Zhang X, Ungaro RC, Colombel JF, Turner D, Kappelman MD, Ruemmele FM. Benign Evolution of SARS-Cov2 Infections in Children With Inflammatory Bowel Disease: Results From Two International Databases. *Clin Gastroenterol Hepatol*. 2021 Feb;19(2):394-396.e5. PMID: 33059040.
15. Brenner EJ, Ungaro RC, Colombel JF, Kappelman MD. IBD in the COVID-19 era: the value of international collaboration. *Lancet Gastroenterol Hepatol*. 2020 Oct;5(10):887-888. PMID: 32941833.
16. Brenner EJ*, Ungaro RC*, Geary RB, Kaplan GG, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Ruemmele FM, Steinwurz F, Underwood FE, Zhang X, Colombel JF, Kappelman MD. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. *Gastroenterology*. 2020 Aug. PMID: 32425234.
17. Brenner EJ, Kappelman MD. Working Together to Meet the Needs of Patients With Inflammatory Bowel Diseases. *Clin Gastroenterol Hepatol*. 2021 Jan;19(1):210-211. PMID: 32246997.

*Denotes co-first authorship

**Denotes co-last authorship